Pharma news outlet "Endpoints" apparently thought that their first headline announcing blood clots was a bit to eye catching, the wrong kind of eye catching, and changed the title of their Covid 19 Roundup article from the former to the latter. They went from the vaccine unfriendly heading, to the puff piece title. This of course had the effect of making many Twitter and facebook posts calling attention to the blood clot problem look a bit confusing.
They then bury the blood clot disclosure third in the on the subjects in the article:
"Norway joins growing chorus of EU nations halting AstraZeneca rollout in wake of blood clot reports
On the heels of some European Union members refusing to allow the AstraZeneca/Oxford University vaccine to leave their shores last week, others are now halting distribution of the shot due to reports of blood clots.
Denmark and Austria temporarily suspended rollout of the vaccine on Wednesday after an individual was diagnosed with blood clots and died 10 days after receiving the shot, while another is recovering in the hospital from a pulmonary embolism. And early Thursday, Norway joined the growing list of countries pausing their AstraZeneca vaccine rollout programs, Reuters reported.
The EMA is currently reviewing the cases, and said in a statement that there’s currently no indication that the vaccines caused the events.
“The information available so far indicates that the number of thromboembolic events in vaccinated people is no higher than that seen in the general population,” the EMA’s safety committee PRAC said in a statement Wednesday.
Blood clots are not listed as a side effect for the vaccine, PRAC added.
Danish and Austrian authorities have said they are taking these steps out of an abundance of caution. The vaccine’s use in Denmark will be paused for 14 days.
The issue, the EMA says, potentially deals with a specific batch of AstraZeneca vaccine that was shipped to 17 EU countries and contained 1 million shots. In addition to Austria and Denmark, four other nations have curtailed administration as of Tuesday: Estonia, Lithuania, Luxembourg and Latvia.
Though the EMA has said a quality defect is “unlikely,” the batch is being investigated.
News of the suspensions comes as AstraZeneca has run into hiccups across the continent trying to distribute its vaccine, created in conjunction with Oxford University. Last week, Italy prevented a vaccine shipment destined for Australia from leaving its borders, marking the first instance of an EU nation taking advantage of new rules governing such shipments outside the bloc that were implemented in late January.
The drugmaker has also seen slow uptake around the world after fighting with the EU publicly over the doses promised in its contracts. And some people in European countries are reportedly shunning the vaccine in favor of mRNA-based shots with higher topline efficacy levels. — Max Gelman"